Last updated: March 1, 2026
What is the drug associated with NDC 42794-0017?
The NDC 42794-0017 corresponds to TAVNEOS (avacopan), a prescription medication approved by the FDA for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). It is a selective complement 5a receptor inhibitor designed to reduce inflammation by blocking the C5a receptor.
Market landscape overview
Current approvals and indications
- FDA approval date: October 2021
- Indications:
- Adult patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)—both forms of ANCA-associated vasculitis
- Used as an adjunct to standard-of-care immunosuppressive therapy
- Market exclusivity:
- Orphan drug designation granted, providing seven years of market exclusivity from approval date
Key competitors
| Drug |
Mechanism |
Approval Year |
Market Share (2022) |
Price (per treatment course) |
| Rituximab |
CD20+ B-cell depletion |
2011 |
50% |
$32,000 |
| Cyclophosphamide |
Alkylating agent |
Approved early 2000s |
20% |
$4,000 |
| Mepolizumab |
IL-5 inhibitor (adjunct) |
Approved 2019 |
10% |
$30,000 |
| TAVNEOS (avacopan) |
Complement 5a receptor inhibitor |
2021 |
Emerging |
~$45,000 per course |
Market size estimation
- Prevalence: ANCA-associated vasculitis affects approximately 3 cases per 100,000 annually in the U.S.
- Patient population: Estimated 8,000–10,000 patients eligible for new therapies annually.
- Total addressable market (TAM): Estimated at $300–$400 million in the U.S. alone, considering various treatment costs and patient access.
Adoption barriers and drivers
-
Barriers:
- Competition from established therapies
- High treatment costs
- Limited awareness among clinicians due to recent approval
-
Drivers:
- Favorable safety profile
- Orphan drug status removes competition for seven years
- Growing approval for use in broader vasculitis forms
Price projections
Short-term (2023–2025)
- Initial pricing:
- Launched at approximately $45,000 per treatment course, aligning with similar biologics.
- Market penetration:
- Limited initial uptake due to clinician familiarity with existing therapies
- Estimated 10–15% adoption in the first 2 years
- Revenue estimate:
- Year 1: ~$20 million
- Year 2: ~$45 million
Mid-term (2026–2030)
- Price adjustments:
- Potential discounts to improve market penetration
- Possible generic or biosimilar competition after orphan exclusivity expires in 2028
- Market growth rate:
- 15–20% annually, driven by increased acceptance and expanded indications
- Revenue estimate:
- 2030: $150–200 million, assuming significant clinical adoption and optimized pricing strategies
Long-term (post-2030)
- Generic/biosimilar impact:
- Market share could decline by up to 50% if biosimilars enter, decreasing prices to ~$20,000–$30,000 per course
- Pricing trends:
- Continued downward pressure but stabilized by clinical efficacy and reputation
Key considerations
- Pricing elasticity is limited due to the orphan drug status and high R&D costs.
- Market access and reimbursement policies will significantly influence net prices.
- Clinician adoption hinges on demonstrating clinical advantages over existing therapies, particularly in safety and tolerability.
Key Takeaways
- NDC 42794-0017 (TAVNEOS) entered a niche market for AAV with limited direct competition but faces strong competition from established biologics like rituximab.
- The initial treatment course price is projected around $45,000, with revenues expected to scale up as adoption increases.
- Market growth hinges on clinical acceptance, reimbursement policies, and the expiration of orphan exclusivity—anticipated in 2028.
- Competition from biosimilars will likely impact prices post-2030, potentially reducing treatment costs significantly.
FAQs
1. How does TAVNEOS compare to existing therapies in efficacy?
Clinical trials show TAVNEOS offers comparable or improved safety and efficacy profiles, especially in reducing relapse rates. However, long-term data is still emerging.
2. What is the potential for off-label use?
Off-label use remains limited due to the drug's recent approval and specific orphan indication, but future research could expand its applications.
3. How will pricing be affected once biosimilars enter the market?
Biosimilar entry typically reduces biologic drug prices by 20–50%, influencing TAVNEOS’s market share and reimbursement rates.
4. Are there regional pricing differences?
Yes. The U.S. tends to have higher drug prices compared to Europe and Asia, where pricing and reimbursement policies vary.
5. What market factors could influence long-term growth?
Expanded indications, real-world evidence supporting superior efficacy or safety, and pricing strategies will shape long-term growth.
Sources:
[1] U.S. Food and Drug Administration. (2021). TAVNEOS (avacopan): Prescribing information.
[2] IQVIA. (2022). Market analytics for rare and orphan drugs.
[3] EvaluatePharma. (2022). Orphan and rare disease market forecasts.
